Results 131 to 140 of about 5,873,527 (237)

Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double‐Blind Randomised Placebo‐Controlled Trial

open access: yesAllergy, EarlyView.
This is the first randomised placebo‐controlled trial of intralymphatic immunotherapy using a microcrystalline tyrosine‐adjuvanted grass pollen allergoid. Three ultrasound‐guided ILIT injections were well tolerated and reduced combined symptom‐medication scores compared with placebo. The findings support further optimisation and clinical development of
Lara Šošić   +13 more
wiley   +1 more source

In vivo efficient maternal haploid production in melon via knockout of CmDMP genes. [PDF]

open access: yesPlant Physiol
Zhang L   +7 more
europepmc   +1 more source

Factors for Success and Failure of Allergen Immunotherapy (AIT) Trial Design in the Light of Evidence‐Based Medicine: Current Aspects 2026

open access: yesAllergy, EarlyView.
ABSTRACT Allergen immunotherapy (AIT) has been acknowledged as the only disease‐modifying treatment for respiratory diseases since its introduction in 1911. Although the efficacy and safety have convincingly been established in numerous randomized clinical trials (RCTs), the AIT study results may vary substantially.
Roy Gerth van Wijk   +10 more
wiley   +1 more source

Editing CsPOD7 triggers in vivo maternal haploid induction in cucumber. [PDF]

open access: yesJ Integr Plant Biol
Li S   +12 more
europepmc   +1 more source

Assessing bullying, being bullied, and self-concept : a psychometric evaluation of the Adolescent Peer Relations Instrument and Self-Description Questionnaire II for upper primary aged children

open access: yes, 2006
Research on school bullying tends to focus on single-item item rather than scale-based questionnaires, the former of which do not take into consideration the different types of bullying which can take place.
Finger, Linda R.   +2 more
core  

Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

open access: yesAllergy, EarlyView.
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov   +43 more
wiley   +1 more source

As‐Needed Versus Regular Medication Use in the Treatment of Allergic Rhinitis in the Pollen Season: A MASK‐air Study

open access: yesAllergy, EarlyView.
Using MASK‐air app data from 1042 users across 2690 weeks, this study compared the impact of regular versus as‐needed allergic rhinitis medication on symptom control and treatment satisfaction. Mixed‐effects linear regression models and sensitivity analyses revealed no significant differences between the two approaches, with results for oral ...
Bernardo Sousa‐Pinto   +38 more
wiley   +1 more source

Home - About - Disclaimer - Privacy